The present disclosure relates generally to compositions and methods of treating cancers, such as glioblastoma and non-Hodgkin’s lymphomas, or other cancers in which the subject suffers from an advanced solid tumor, comprising the administration of a bromodomain and extra-terminal protein (BET) inhibitor and at least one chemotherapeutic agent, which does not inhibit BET directly. The BET inhibitor/chemotherapeutic agent combination therapy can yield synergistic effects, thereby increasing the effectiveness of the cancer treatment as compared to the administration of either the BET inhibitor or the chemotherapeutic agent alone.本揭示案總體上係關於治療諸如神經膠質母細胞瘤及非何傑金氏淋巴瘤等癌症或其他癌症的組合物及方法,在該等其他癌症中受試者患有晚期實體腫瘤,該等組合物及方法包含投與溴結構域及額外末端蛋白質(BET)抑制劑及至少一種化學治療劑,該至少一種化學治療劑不直接抑制BET。該BET抑制劑/化學治療劑組合療法可產生協同作用,從而與單獨投與該BET抑制劑或該化學治療劑相比,增加該癌症治療之有效性。
